Stocks and Investing
Stocks and Investing
Tue, January 26, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Benjamin Burnett Upgraded (ALLO) to Strong Buy and Increased Target to $43 on, Jan 26th, 2021
Benjamin Burnett of Stifel, Upgraded "Allogene Therapeutics, Inc." (ALLO) to Strong Buy and Increased Target from $33 to $43 on, Jan 26th, 2021.
Benjamin has made no other calls on ALLO in the last 4 months.
There are 2 other peers that have a rating on ALLO. Out of the 2 peers that are also analyzing ALLO, 0 agree with Benjamin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Benjamin
- Robert Burns of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $40 on, Thursday, December 10th, 2020
- Luca Issi of "RBC Capital" Initiated at Buy and Held Target at $55 on, Friday, October 23rd, 2020
Contributing Sources